11
Jun 2026
A large MRI study of more than 47,000 adults found that cerebellar aging is uneven, with posterior association regions and some motor-related areas showing steeper age-related changes. Larger cerebellar volumes were linked to better cognitive performance, supporting a threshold-reserve model in which the cerebellum may help sustain cognition before Alzheimer’s pathology becomes widespread.
11
Jun 2026
JMIR Publications released a News and Perspectives story on technological innovations in women's health care.
11
Jun 2026
Boston Children's Hospital has been awarded up to $17.25 million to serve as a participating site within the Innovative Medicine and Precision Approaches to Clinical Trials (IMPACT) Network, an international effort funded through Aligning Research to Impact Autism (ARIA).
11
Jun 2026
A new AI model has become so good at predicting how molecules evolve over time that, in the future, it could speed up the costly and time-consuming process of testing new drugs.
11
Jun 2026
In a landmark achievement in biological imaging, researchers at the University of California, Berkeley and Biohub today announced the successful demonstration of the laser phase plate, a novel device that dramatically improves the contrast of images produced by cryo-electron microscopes, opening up an entirely new view of human biology.
11
Jun 2026
A nationwide Finnish registry study of 7,249 GLP-1RA-naïve adults with type 2 diabetes found that once-daily oral semaglutide was associated with 12-month improvements in HbA1c, body weight, lipid markers, and ALT.
11
Jun 2026
A nationwide Finnish registry study of 7,249 GLP-1RA-naïve adults with type 2 diabetes found that once-daily oral semaglutide was associated with 12-month improvements in HbA1c, body weight, lipid markers, and ALT.
11
Jun 2026
A nationwide Finnish registry study of 7,249 GLP-1RA-naïve adults with type 2 diabetes found that once-daily oral semaglutide was associated with 12-month improvements in HbA1c, body weight, lipid markers, and ALT.
11
Jun 2026
A one-year randomized trial found that daily prune supplementation did not improve total or lumbar spine bone mineral density in older men susceptible to, or with, osteopenia. Although some bone turnover biomarkers differed between prune and control groups, these changes did not translate into measurable bone density benefits beyond calcium and vitamin D3 supplementation.
11
Jun 2026
Once-daily oral elecoglipron produced dose-dependent weight loss in adults with obesity or overweight without diabetes, with mean reductions reaching 10.5% at 26 weeks and 11.8% at 36 weeks in the highest-dose weekly-titration group. The phase 2 trial found no evidence of a weight-loss plateau by 36 weeks, while gastrointestinal adverse events were common but generally manageable.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
